NCT04219254 - A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) | Biotech Hunter

Enrollment

197

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Solid Tumor, Adult

Interventions

DRUG

BI1206

"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"

Trial Locations (7)

55101

RECRUITING

HealthPartners Institute - Regions Cancer Care Center,, Saint Paul

73104

RECRUITING

Oklahoma University , Stephenson Cancer Center, Oklahoma City

78229

ACTIVE_NOT_RECRUITING

NEXT Oncology, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute, Denver

Unknown

RECRUITING

Sahlgrenska University Hospital, Gothenburg

RECRUITING

Lund University Hospital, Lund

RECRUITING

Karolinska University Hospital, Solna, Stockholm